LAB 📈 Standard Biotools - Overview

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US34385P1084

LAB: Analytical Systems, Genomics Instruments, Reagents, Software, Consumables

Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument. It also provides genomics, such as X9 Real-Time PCR System, a real-time PCR analytical instrument including pre-processing steps for microfluidics-based workflows using (integrated fluidic circuit) IFCs; and IFC Controllers, a controller which is designed to work with IFC formats. In addition, the company offers analytical instruments comprising Biomark HD system, a real-time PCR analytical instrument for microfluidics-based workflows using prepared IFCs. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California. Web URL: https://www.standardbio.com

Additional Sources for LAB Stock

LAB Stock Overview

Market Cap in USD 797m
Sector Healthcare
Industry Medical Devices
GiC Sub-Industry Life Sciences Tools & Services
IPO / Inception 2003-07-29

LAB Stock Ratings

Growth 5y -51.9%
Fundamental -50.7%
Dividend -
Rel. Strength Industry -29.5
Analysts 5/5
Fair Price Momentum 1.65 USD
Fair Price DCF -

LAB Dividends

No Dividends Paid

LAB Growth Ratios

Growth Correlation 3m 13.5%
Growth Correlation 12m -65.1%
Growth Correlation 5y -63.9%
CAGR 5y -10.05%
CAGR/Mean DD 5y -0.16
Sharpe Ratio 12m 0.36
Alpha -49.92
Beta 2.14
Volatility 102.03%
Current Volume 4657.1k
Average Volume 20d 1603.8k
What is the price of LAB stocks?
As of December 21, 2024, the stock is trading at USD 2.00 with a total of 4,657,077 shares traded.
Over the past week, the price has changed by +4.71%, over one month by +24.22%, over three months by -0.50% and over the past year by +3.63%.
Is Standard Biotools a good stock to buy?
No, based on ValueRay Fundamental Analyses, Standard Biotools (NASDAQ:LAB) is currently (December 2024) a stock to sell. It has a ValueRay Fundamental Rating of -50.74 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of LAB as of December 2024 is 1.65. This means that LAB is currently overvalued and has a potential downside of -17.5%.
Is LAB a buy, sell or hold?
Standard Biotools has received a consensus analysts rating of 5.00. Therefor, it is recommend to buy LAB.
  • Strong Buy: 3
  • Buy: 0
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0
What are the forecast for LAB stock price target?
According to ValueRays Forecast Model, LAB Standard Biotools will be worth about 1.9 in December 2025. The stock is currently trading at 2.00. This means that the stock has a potential downside of -5.5%.
Issuer Forecast Upside
Wallstreet Target Price 3.1 54%
Analysts Target Price 0.6 -72.5%
ValueRay Target Price 1.9 -5.5%